Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clopidogrel · 3 trials · 5 indications
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP.
| Arm | Type | Description |
|---|---|---|
| Clopidogrel - for CYP2C19*2 carriers | ACTIVE_COMPARATOR | Clopidogrel for CYP2C19\*2 gene carriers |
| Clopidogrel - for CYP2C19*2 non-carriers | ACTIVE_COMPARATOR | Clopidogrel for CYP2C19\*2 gene NON-carriers |
| Clopidogrel + Aspirin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Aspirin | DRUG | - |
| Clopidogrel | DRUG | - |
Inclusion Criteria: * Patients 18 years of age or older * Undergoing on-pump, elective coronary artery bypass grafting with at least 2 free grafts * Patient able to give informed consent Exclusion Criteria: * planned date of surgery is \<5 days from planned recruitment date * patient has clear in...